Skip to content

Evaluation of Reactive Oxygen Metabolites in the Value of COPD

System Evaluation of Reactive Oxygen Metabolites in the Value of Chronic Obstructive Pulmonary Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02297633
Enrollment
320
Registered
2014-11-21
Start date
2014-10-31
Completion date
2017-07-31
Last updated
2014-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD(Chronic Obstructive Pulmonary Disease)

Keywords

COPD, reactive oxygen metabolites

Brief summary

This study through the long-term observation followed up for 2 years to find the change of the COPD patients blood ROMs, systematically evaluate the relationship between ROMs and the severity of COPD. Evaluate the differences of prognosis between the different oxidative stress level (according to the level of ROMs are divided into higher and normal phenotype). Explore the new oxidative stress evaluation index ROMs application value in COPD.

Detailed description

Reactive oxygen metabolites (reactive oxygen metabolites, ROMs) test is a method by measuring the total reactive oxygen metabolites (ROMs) content in blood so as to evaluate the overall level of oxidative stress in the human body .Our previous studies have established the method of detecting ROMs which is suitable for fully automatic biochemical analyser.Our study through the long-term observation followed up for 2 years to find the change of the COPD patients blood ROMs, systematically evaluate the relationship between ROMs and the severity of COPD. Evaluate the differences of prognosis between the different oxidative stress level (according to the level of ROMs are divided into higher and normal phenotype). Explore the new oxidative stress evaluation index ROMs application value in COPD.

Interventions

None listed

Sponsors

Beijing Chao Yang Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Clinical diagnosis of COPD according to GOLD 2013

Exclusion criteria

* A history of asthma or other chronic lung diseases Take Antioxidant therapy There are new or recurrent symptomatic myocardial ischemia, severe arrhythmia, cardiac insufficiency cerebrovascular disease Senile dementia or cognitive impairment cancer Severe liver and kidney and other viscera function insufficiency Language communication barriers Limb activity disorder The last 3 months participated in sports training

Design outcomes

Primary

MeasureTime frameDescription
The different levels of the ROMs among different groups3 yearsApply the analysis of variance to compare the different levels of ROMs among the four different groups

Secondary

MeasureTime frameDescription
The differences of the ROMs among the different lung function levels in the stable stage of COPD group3 yearsApply the analysis of variance to compare the differences of the ROMs among the lung function levels in the stable stage of COPD group.
The relevance of the ROMs with the lung function levels in the stable stage of COPD group3 yearsApply Pearson correlation to compare relevance the of the ROMs with the lung function levels in the stable stage of COPD group.
The relevance of the ROMs with the score of mMRC in the stable stage of COPD group3 yearsApply Pearson correlation to compare relevance the of the ROMs with score of mMRC in the stable stage of COPD group.
The relevance of the ROMs with the score of CAT in the stable stage of COPD group3 yearsApply Pearson correlation to compare relevance the of the ROMs with score of CAT in the stable stage of COPD group.
The relevance of the ROMs with the numbers of exacerbation in the stable stage of COPD group3 yearsApply Pearson correlation to compare relevance the of the ROMs with numbers of exacerbation in the stable stage of COPD group.

Countries

China

Contacts

Primary ContactTing Yang, Doctor
dryangting@qq.com13651380809
Backup ContactJie Liu, Master
chaoyangliujie@163.com18811225394

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026